Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss

Sodhi, Mohit; Rezaeianzadeh, Ramin; Kezouh, Abbas; Etminan, Mahyar

doi:10.1001/jama.2023.19574

articleJAMAOct 5, 2023GREEN OA

Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss

MSMohit Sodhi RRRamin Rezaeianzadeh AKAbbas Kezouh MEMahyar Etminan

University of British Columbia

PubMed

Indexed incrossrefpubmed

Abstract

This database study examines the association between glucagon-like peptide 1 agonists (eg, semaglutide, liraglutide) used for weight loss and reports of gastrointestinal adverse events.

Citation impact

414

total citations

FWCI: 74.27
Percentile: 100%
References: 9

Citations per year

Authors

4

Topics & keywords

Topics

Keywords

Medicine
Semaglutide
Liraglutide
Adverse effect
Weight loss
Glucagon
Glucagon-like peptide 1 receptor
Glucagon-like peptide-1

UN Sustainable Development Goals

Good health and well-being

No related works found for this paper.